Rosario Pedro Weslley, Mourão Gabriela Franco, Calsolari Maria Regina
Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.
Eur Thyroid J. 2019 Jan;8(1):41-45. doi: 10.1159/000493978. Epub 2018 Nov 16.
Periodic ultrasonography (US) examination is recommended in many patients with papillary thyroid carcinoma (PTC) after treatment with radioactive iodine (RAI), but recurrences are confirmed in few cases. This study determined whether the indication of US in the first years after treatment with RAI can be selective when postoperative US and posttherapy whole-body scanning (RxWBS) ruled out persistent neck disease.
This was a prospective study. Two hundred and fifty-four patients with PTC (242 of intermediate risk) undergoing thyroidectomy and RAI, who had no apparent disease at the time of initial therapy (including negative postoperative US and RxWBS), were studied. The patients were followed up for 5 years after treatment with RAI by annual US.
At the end of 5 years, 47 patients (18.5%) had at least one suspicious US, but neck recurrence was confirmed in only 4 patients (1.5% of all patients and 8.5% of those with suspicious US). The remaining cases were considered false-positives. US did not reveal disease in the first or second year after treatment with RAI in any patient. In the third, fourth, and fifth year after treatment with RAI, considering only patients with unstimulated Tg < 1 ng/mL in these assessments, US revealed disease in 0, 1 (0.4%), and 1 (0.4%) patient, respectively.
The results suggest that low- or intermediate-risk patients with PTC without persistent disease after thyroidectomy (including negative postoperative US and RxWBS) do not require repeat US examination in the first two years after treatment with RAI. In the following years until the fifth year, US can be restricted to patients with Tg ≥1 ng/mL.
对于许多接受放射性碘(RAI)治疗后的甲状腺乳头状癌(PTC)患者,建议进行定期超声(US)检查,但很少有病例证实复发。本研究确定,当术后US和治疗后全身扫描(RxWBS)排除颈部持续性疾病时,RAI治疗后最初几年US检查的指征是否可以具有选择性。
这是一项前瞻性研究。对254例接受甲状腺切除术和RAI治疗的PTC患者(242例为中度风险)进行了研究,这些患者在初始治疗时无明显疾病(包括术后US和RxWBS阴性)。患者在接受RAI治疗后通过每年的US随访5年。
在5年结束时,47例患者(18.5%)至少有一次可疑的US检查结果,但仅4例患者(占所有患者的1.5%,占可疑US检查结果患者的8.5%)被证实颈部复发。其余病例被认为是假阳性。在接受RAI治疗后的第一年或第二年,没有患者的US检查发现疾病。在接受RAI治疗后的第三、第四和第五年,仅考虑这些评估中未刺激Tg<1 ng/mL的患者,US分别在0例、1例(0.4%)和1例(0.4%)患者中发现疾病。
结果表明,甲状腺切除术后无持续性疾病(包括术后US和RxWBS阴性)的低风险或中度风险PTC患者在接受RAI治疗后的前两年不需要重复US检查。在接下来直到第五年的时间里,US检查可仅限于Tg≥1 ng/mL的患者。